|
Fibrodysplasia Ossificans Progressiva
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In addition, an RAR-γ agonist blocked heterotopic ossification in transgenic mice expressing activin receptor-like kinase-2 (ALK2) Q207D, a constitutively active form of the receptor that is related to ALK2 R206H found in individuals with fibrodysplasia ossificans progressiva.
|
21460849 |
2011 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
The functional consequence of the interplay between c-Myc oncogene expression and the RARγ to RARα/β balance suggests that prevalence of RARγ over-RARα/β expression levels in breast cancer accompanied by c-Myc amplification or over-expression in breast cancer should be predictive of response to treatment with RARα-isotype-specific agonists and warrant monitoring during clinical trials.
|
22920668 |
2012 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Modulation of the RARα/β to RARγ expression in mammary glands of normal mice, oncomice, and human mammary cell lines through the alteration of RAR-target gene expression affected cell proliferation, survival and tumor growth.
|
22920668 |
2012 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The functional consequence of the interplay between c-Myc oncogene expression and the RARγ to RARα/β balance suggests that prevalence of RARγ over-RARα/β expression levels in breast cancer accompanied by c-Myc amplification or over-expression in breast cancer should be predictive of response to treatment with RARα-isotype-specific agonists and warrant monitoring during clinical trials.
|
22920668 |
2012 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.
|
22920668 |
2012 |
|
leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
The regulation of the subcellular content of CDK1 and RARγ by ATRA is an important process for achieving an effective response in treatment of leukemia.
|
23518499 |
2013 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia.
|
23518499 |
2013 |
|
Childhood Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
The regulation of the subcellular content of CDK1 and RARγ by ATRA is an important process for achieving an effective response in treatment of leukemia.
|
23518499 |
2013 |
|
Cholangiocarcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
However, the role of RARγ in cholangiocarcinoma (CCA), chemoresistant bile duct carcinoma with a poor prognosis, remains unclear.
|
23798555 |
2013 |
|
Papillary thyroid carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we found significantly increased expression of RARα and RARγ in the overall group of PTC.
|
23969901 |
2013 |
|
Congenital contractural arachnodactyly
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggested that RARγ plays an important role in the proliferation, metastasis, and chemoresistance of CCA through simultaneous activation of the Akt/NF-κB and Wnt/β-catenin pathways, serving as a potential molecular target for CCA treatment.
|
23798555 |
2013 |
|
Bile duct carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the role of RARγ in cholangiocarcinoma (CCA), chemoresistant bile duct carcinoma with a poor prognosis, remains unclear.
|
23798555 |
2013 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Differentiation of T1338 was induced by RARα and RARγ isotype-selective retinoids, associated with down-regulation of Sox2, and the failure to induce orthotopic tumors in the brains of SCID mice.
|
25171789 |
2014 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
Here we investigated the novel BH3 domain mimetic, JY-1-106, which antagonizes the anti-apoptotic BCL-2 family members B-cell lymphoma-extra large (BCL-xL) and myeloid cell leukemia-1 (MCL-1) alone and in combination with retinoids including atRA, AM580 (RARα agonist), and SR11253 (RARγ antagonist).
|
25088254 |
2014 |
|
Cardiotoxicity
|
0.400 |
Biomarker
|
disease |
CTD_human |
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
|
26237429 |
2015 |
|
Cardiotoxicity
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
|
26237429 |
2015 |
|
Heart Diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
|
26237429 |
2015 |
|
Malignant Childhood Neoplasm
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
|
26237429 |
2015 |
|
Malignant Childhood Neoplasm
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.
|
26237429 |
2015 |
|
leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Critical role of retinoid/rexinoid signaling in mediating transformation and therapeutic response of NUP98-RARG leukemia.
|
25510432 |
2015 |
|
Childhood Leukemia
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Critical role of retinoid/rexinoid signaling in mediating transformation and therapeutic response of NUP98-RARG leukemia.
|
25510432 |
2015 |
|
Refractory anemias
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We show that KLF2 induces the expression of CRABP2 and RARγ and inhibits the expression FABP5 and PPARβ/δ thereby shifting RA signaling from the pro-carcinogenic FABP5/PPARβ/δ to the growth-suppressing CRABP2/RAR path.
|
26416422 |
2015 |
|
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We show that KLF2 induces the expression of CRABP2 and RARγ and inhibits the expression FABP5 and PPARβ/δ thereby shifting RA signaling from the pro-carcinogenic FABP5/PPARβ/δ to the growth-suppressing CRABP2/RAR path.
|
26416422 |
2015 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We described applications that show how investigating the behaviour of FFLs in glioblastoma can reveal FFLs (such as RARG-NR1I2-CDX2) that are associated with prognosis.
|
26526635 |
2015 |
|
Acute leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
While the nucleoporin 98-retinoic acid receptor gamma (NUP98-RARG) is the first RARG fusion protein found in acute leukemia, its roles and the molecular basis in oncogenic transformation are currently unknown.
|
25510432 |
2015 |